Business Assets for Sale

Our game is a successful product sold in several countries and in several languages. This company as a licensed seller, announces the sale of the license right for the board game, the duration of which is 5 or 10 years. The license right sale includes the following: • 5 or 10-year right, which gives buyer the exclusive right to sell the companion. The game within the country is included in the contract. This applies to both traders and private individuals. • Complete translation and proofreading of the game to the agreed language mutation. • Graphic design of the game, complete printing graphics of the game, which you can send as finished material to the selected printing house. • Tantra massage video narration for the selected language mutation. • Preparation of a presentation in the selected language for your future partners. • Tantra massage video link, which the customer can download, since the video is part of the game. • Supplier contact information for purchasing game accessories. (If required) By purchasing the license right, we claim the following: • The quality of the printing production must match the quality of the board. We will need a sample of the game (translated copy) and the props. • The quality of the game props must match the quality of the props we manufacture. • The website used to sell the game must be similar to the original website. • Buyer can only sell the board game in the country indicated in the contract.

Start-up owns a formula of medicine that prevents and/or treats coronavirus symptoms. - It is an alternative medicine due to its all-natural and herbal ingredients. - Potential market will be the segment of the world population who decline vaccines and another potential market can be the vaccinated who need the added support. - List of ingredients will be disclosed upon sale of the medicine formula. - The medicine has been developed by a university and this start-up owns the formula. - Currently, the only asset available for sale is the all-natural Covid-19 medicine formula. - Patent approval is in pending status.

This sale includes only the sale of machinery and raw materials. We specialize in producing plastic granules (HD-PE, LD-PE, PP, PET) and wood sawdust briquettes. The productivity of PET production is processing 5 tons of raw materials in 1 day. The productivity of PP. HD PE, LD PE is 4.5 tons per day. We currently have pressed raw materials in stock which will also be a part of this sale. Any plastic manufacturer can acquire these assets and start or expand their operations. There are no loans or debts associated with the assets on sale. The business is not operational right now.

This is an asset sale only. - Includes machinery for the production of paper carry bags and inventory. - The bags, both printed and unprinted, are primarily supplied to retail food outlets. - Paper carry bags are widely used as eco-friendly packaging solutions, especially by retail food outlets for takeaway and grocery items. - The machinery includes three paper bag machines, a six-color flexographic printing machine, a slitting machine, and taping lines. - The machinery has a capacity of 3 million units per month and was regularly used to produce 2 million units each month. - The machinery is worth EUR 1.5 million and the inventory is worth EUR 500K.

7,18,000 sq. ft. of land located next to a non-operational coal mine. - The owner has a valid registration certificate of the land. - The site’s proximity to an existing coal reserve provides a strong foundation for mining or coal-based industrial projects. - Currently non-operational, presenting an opportunity for investors or companies to develop coal trading, processing, or power generation facilities. - The land offered is versatile and suitable for multiple purposes, including use as a coal dumping yard, storage yard, office premises or real estate development.

The company is selling perpetual usage rights of an AI platform that analyzes microbiome and health data to deliver personalized nutrition and wellness plans. - Partners can deploy and white-label the platform locally, offering premium, data-driven health solutions under their own brand. - The sale includes the proprietary core AI algorithms and source code for the microbiome-based precision diet technology. - Partners receive the right to unlimited API access and the ability to customize and train the AI with local data, ensuring relevance and effectiveness in their market. - The license also grants the right to localized deployment on the partner's local servers for compliance and security, and the autonomy to operate and brand the AI as their own. - The capacity of the AI model is virtually unlimited as it is scalable to the partner's server infrastructure, and its condition is excellent, being actively maintained by us. - The tangible assets required for the operation are minimal and fall primarily under the partner's operational responsibility, reflecting a lean, software-driven business model. - The partner is responsible for managing the inventory of sample collection kits (optional cost of GBP 7.5 per kit), requiring only a small fulfillment/warehouse space for storage and shipping. - We have successfully validated our technology on a global scale, processing over 50,000 microbiome samples across 15+ countries and securing strategic partnerships with major industry players. - Our deep-tech innovation has been recognized with prestigious global awards, including the UK Tech Rocketship Award and victories in the Sanofi and Bayer accelerator programs, establishing us as a trusted leader in the personalized health sector. - The business is driven by a seasoned leadership team, including a serial entrepreneur CEO and a CTO with 15+ years of bioinformatics expertise, ensuring clinical validity and robust architecture. - You can establish a high-margin, end-to-end health service by integrating our software with local Next-Generation Sequencing (NGS) laboratories. - In this model, our partner manages the complete value chain: collecting biological samples, processing them locally, and utilizing our AI to generate premium precision diet and health reports. - These complete diagnostic packages are then sold directly to consumers, medical clinics, and hospitals, allowing the partner to capture the full market value of every test performed. - Alternatively, you can leverage your exclusive regional rights to create a scalable B2B sublicensing ecosystem. - Acting as a master distributor, one can sublicense the software access to other local laboratories, wellness apps, and healthcare networks within the territory. - This allows to generate significant recurring revenue by charging own clients for API access or white-labeled portals, effectively monetizing the technology across the entire region without needing to manage every sample personally. - The company is headquartered in London, while the promoter is currently based in the US and has provided that number for all communications.